Evidence map›Paper›PMID 32193618›Full record

ArticleCancer chemotherapy and pharmacology2020

Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.

Ou Yamaguchi, Hisao Imai, Hiroyuki Minemura, Kensuke Suzuki, Satoshi Wasamoto, Yukihiro Umeda, Takashi Osaki, Norimitsu Kasahara, Junji Uchino, Tomohide Sugiyama and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 6 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 6 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 1 country.

Ou YamaguchiDepartment of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
Hisao Imai *Division of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1, Takahayashinishi, Ota, Gunma, 373-8550, Japan. m06701014@gunma-u.ac.jp.
Hiroyuki MinemuraDepartment of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
Kensuke SuzukiDivision of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Toyama, Japan.
Satoshi WasamotoDivision of Respiratory Medicine, Saku Central Hospital Advanced Care Center, Saku, Nagano, Japan.
Yukihiro UmedaThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui, Japan.
Takashi OsakiDivision of Respirology, National Hospital Organization Shibukawa Medical Center Hospital, Shibukawa, Gunma, Japan.
Norimitsu KasaharaDepartment of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Junji UchinoDepartment of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
Tomohide SugiyamaDivision of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.
Shinichi IshiharaDepartment of Internal Medicine, Isesaki Municipal Hospital, Isesaki, Gunma, Japan.
Hisashi IshiiDepartment of Pulmonary Medicine, Nishisaitama-Chuo National Hospital, Tokorozawa, Saitama, Japan.
Ichiro NaruseDivision of Respiratory Medicine, Hidaka Hospital, Takasaki, Gunma, Japan.
Keita MoriClinical Research Promotion Unit, Clinical Research Center, Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan.
Mie KotakeDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1, Takahayashinishi, Ota, Gunma, 373-8550, Japan.
Kenya KanazawaDepartment of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
Koichi MinatoDivision of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1, Takahayashinishi, Ota, Gunma, 373-8550, Japan.
Hiroshi KagamuDepartment of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
Kyoichi KairaDepartment of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
Saitama Medical University · JPFukushima Medical University · JPGunma University · JPHidaka Hospital · JPIsesaki Fukushima Hospital · JPKyoto Prefectural University of Medicine · JPNational Hospital Organization · JPSaku Central Hospital · JPShizuoka Cancer Center · JPTochigi Cancer Center · JPToyama Prefectural Central Hospital · JPUniversity of Fukui · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeImmune checkpoint inhibitors (ICIs) are an effective subsequent-line treatment for patients with advanced non-small cell lung cancer (NSCLC). However, it remains unclear whether the efficacy and safety of subsequent-line ICI monotherapy in elderly patients (aged ≥ 75 years) are similar to that in non-elderly patients. Therefore, we aimed to investigate the efficacy and safety of ICI monotherapy in pretreated elderly patients with NSCLC.

methodsBetween January 2016 and February 2018, 131 elderly patients with advanced NSCLC who received subsequent-line ICI monotherapy at 13 Japanese institutions were enrolled in this study. Baseline characteristics, the efficacy of ICI treatment, and adverse events were evaluated.

resultsNinety-eight men and 33 women (median age 77 [range 75-87] years) were enrolled. Among those who received subsequent-line ICI monotherapy, the overall response, disease control rates, median progression-free survival (PFS), and overall survival (OS) were 27.4%, 61.8%, 4.5 months, and 16.0 months, respectively. Adverse events such as anorexia, fatigue, pneumonitis, and hypothyroidism were observed. There were two treatment-related deaths due to pneumonitis and thrombocytopenia. Subsequent-line ICI monotherapy in patients with good performance status (PS), receiving steroids for immune-related adverse events (irAEs), and exhibiting partial response (PR) was associated with improved PFS, as well as OS in patients with good PS and PR.

conclusionsSubsequent-line ICI monotherapy in elderly patients, with previously treated NSCLC, was effective, safe and showed outcomes equivalent to those in non-elderly patients. Immunotherapy provides a survival benefit for elderly patients, who exhibit its efficacy and a favorable general condition.

Indexed as

AgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleFollow-Up StudiesHumansImmunotherapyLung NeoplasmsMaleNivolumabPrognosisRetrospective StudiesSurvival RateAntibodies, Monoclonal, HumanizedNivolumabpembrolizumabAdvanced non-small cell lung cancerElderly patientsImmune checkpoint inhibitor monotherapyNivolumabPembrolizumabSubsequent-line

Identifiers

PMID32193618
OpenAlexW3012148100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.